DE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Deere & Company · Industrials
$578.39
+22.4% upside to fair value
Grade C
VS
Pfizer Inc. · Healthcare
$26.33
+35.4% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+35.4%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
PFE |
| Current Price |
$578.39 |
$26.33 |
| Fair Value Estimate |
$708.19 |
$35.65 |
| Upside to Fair Value |
+22.4%
|
+35.4%
|
| Market Cap |
$156.2B |
$149.8B |
| Forward P/E |
32.5x
|
19.3x
|
| EV / EBITDA |
18.4x
|
12.9x
|
| Price / Sales |
3.4x
|
2.4x
|
| Price / FCF |
43.7x
|
16.5x
|
| Revenue Growth YoY |
+16.3%
|
-1.2%
|
| Gross Margin |
35.6%
|
70.3%
|
| Operating Margin |
18.5%
|
24.7%
|
| Return on Equity |
18.9%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.29%
|
6.06%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Deere & Company is a leading manufacturer of agricultural, construction, and forestry machinery, with a strong position in production and precision agriculture, small agriculture and turf, and construction and forestry segments. The company benefits from a durable competitive moat driven by its brand, intangible assets, and switching costs, supported by a CEO with deep institutional knowledge and…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
DE |
PFE |
| Zone Low |
$531.14 |
$26.74 |
| Zone High |
$601.96 |
$30.30 |
| In Buy Zone? |
Yes
|
Yes
|